Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ABVC Biopharma Inc ABVC

Healthcare Biotechnology
ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on development products and technologies to combat various diseases. The Company develops its pipeline by tracking medical discoveries or medical device technologies in research institutions in the Asia-Pacific region. It has a pipeline of six drugs and one medical device under development. Its pipeline includes ABV-1504, ABV-1505, ABV-1601, ABV-1701, ABV-1519, and ABV-1703. ABV-1504 is a botanical reuptake inhibitor that targets norepinephrine to treat major depressive disorder (MDD). It is developing ABV-1505 for treating attention deficit hyperactivity disorder (ADHD). It has developed ABV-1601 for treating depression in cancer patients. ABV-1701 is a vitreous substitute for vitrectomy. Its ABV-1519 is used for the treatment of non-small cell lung cancer. ABV-1703 is a drug for advanced, inoperable, or metastatic pancreatic cancer. The Company develops drugs and medical devices derived from plants.


NDAQ:ABVC - Post by User

ABVC Biopharma Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(251)
•••
Post by whytestockson Jan 03, 2024 10:00am
70 Views
Post# 35808534

$460M First Milestone Payment of Global Licensing Fees has t

$460M First Milestone Payment of Global Licensing Fees has t
News; $ABVC $460M First Milestone Payment of Global Licensing Fees has this BioPharma Listing Flying2024-01-03 08:13:35 ET DENVER, Colo., Jan. 3, 2024 ( www.247marketnews.com )- ABVC BioPharma, Inc. (NASDAQ: ABVC) and its subsidiary, BioLite, Inc., stated, this morning, that they received an aggregate of 46 million shares from AiBtl BioPharma Inc. (&#x201C;AiBtl&#x201D;), as its first...ABVC - $460M First Milestone Payment of Global Licensing Fees has this BioPharma Listing Flying

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities